Evidence map›Paper›PMID 41260060›Full record

Observational studyPediatric neurology2026

Longitudinal Characterization of Males With X-Linked Creatine Transporter Deficiency: Final Results of a Multiyear Observational Study.

Judith S Miller, Cristan Farmer, Susan Blair, Simona Bianconi, Natacha Akshoomoff, Irina Anselm, Bruce A Barshop, Lindsey Becker, Amanda E Bennett, Leandra N Berry and 36 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Pediatric neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02931682 (Observational Study of Males With Creatine Transporter Deficiency), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02931682 terminatednot on this map

Observational Study of Males With Creatine Transporter Deficiency

TypeobservationalSponsorUltragenyx Pharmaceutical IncRan2016 to 2022Enrolled50ConditionsCreatine Deficiency, X-linked
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors.

Judith S MillerCenter for Autism Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: MillerJ3@chop.edu.
Cristan FarmerNeurodevelopmental and Behavioral Phenotyping Service, Office of the Clinical Director, National Institute of Mental Health, Bethesda, Maryland.
Susan BlairUltragenyx Pharmaceutical Inc., Novato, California.
Simona BianconiFormerly Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Natacha AkshoomoffDepartment of Pediatrics, University of California San Diego, La Jolla, California.
Irina AnselmDepartment of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Bruce A BarshopDepartment of Pediatrics, University of California San Diego, La Jolla, California.
Lindsey BeckerDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Amanda E BennettCenter for Autism Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Leandra N BerryDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas; Meyer Center for Developmental Pediatrics and Autism, Texas Children's Hospital, Houston, Texas.
Elizabeth M Berry-KravisDepartments of Pediatrics, Neurological Sciences, and Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois.
Aleksandra BrucheyFormerly Lumos Pharma, Austin, Texas.
Anna W ByarsComprehensive Epilepsy Center, Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Tricia CimmsUltragenyx Pharmaceutical Inc., Novato, California.
Kim M CecilDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Maxine CovelloCenter for Autism Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Laura S CubitCenter for Autism Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Tanvi DasDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Robert J DavisLumos Pharma, Austin, Texas.
Madison DryeCenter for Autism Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Can FiciciogluCenter for Autism Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
John B FultonDepartment of Pediatric Behavioral Health, Primary Children's Hospital, Salt Lake City, Utah; Department of Pediatrics, University of Utah, Salt Lake City, Utah.
Robin P Goin-KochelMeyer Center for Developmental Pediatrics and Autism, Texas Children's Hospital, Houston, Texas.
Whitney GuthrieCenter for Autism Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Barbara E HallinanComprehensive Epilepsy Center, Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Fady Hannah-ShmouniSection on Endocrinology and Genetics, National Institutes of Health, Bethesda, Maryland.
Kathryn E GustafsonDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina.
Dwight D KoeberlDivision of Medical Genetics, Department of Pediatrics, Duke University, Durham, North Carolina.
Nicola LongoDivision of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, Utah.
Eva MamakDepartment of Psychology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Saadet Mercimek-AndrewsDivision of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; Faculty of Medicine and Dentistry, Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada.
Claire MichalakDepartment of Pediatrics, Rush University, Chicago, Illinois.
Forbes D PorterDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Samar RahhalDivision of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Linda ReesFormerly Ultragenyx Pharmaceutical Inc., Novato, California.
Gail A SpiridigliozziDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina.
Caitlin StoneDuke Center for Autism and Brain Development, Duke University School of Medicine, Durham, North Carolina.
Nancy R SullivanDivision of Developmental Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
V Reid SuttonDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
Rebecca P ThomasFormerly Center for Autism Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Manisha UdhnaniCenter for Autism Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Susan WaisbrenDivision of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Manton Center for Orphan Disease Research, Boston, Massachusetts.
Michelle XuUltragenyx Pharmaceutical Inc., Novato, California.
Lin ZhangFormerly Ultragenyx Pharmaceutical Inc., Novato, California.
Melanie BrandaburFormerly Ultragenyx Pharmaceutical Inc., Novato, California.
Audrey ThurmNeurodevelopmental and Behavioral Phenotyping Service, Office of the Clinical Director, National Institute of Mental Health, Bethesda, Maryland.

Funding

Neurodevelopmental and Behavioral Phenotyping ZICMH002961 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI THURM, AUDREY · 2017 to 2025
$12.6M
Clinical Investigations of Inborn Errors of MetabolismZIAHD008989 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI PORTER, FORBES · 2020 to 2025
$5.1M
Intramural NIH HHS ZIA HD008989Intramural NIH HHS ZIC MH002961
6 · The paper itself

Abstract

backgroundThe purpose of the Vigilan observational study (ClinicalTrials.gov, NCT02931682) was to prospectively assess the natural history and developmental course of creatine transporter deficiency (CTD).

methodsMales with CTD aged 6 months to 65 years were evaluated at 6-month intervals for up to 4 years. Evaluations included neurodevelopmental assessments of intellectual functioning, adaptive functioning, challenging behaviors and the onset and progression of medical comorbidities.

resultsFifty participants (median age, 7.6 years) were enrolled. The predominant CTD phenotype consisted of significant intellectual disabilities and limited skill development over time. Most participants had a history of febrile or nonfebrile seizures, gastrointestinal symptoms, and growth failure. All participants learned how to walk, 78% developed at least some verbal speech, and 34% communicated using phrases or sentences. Norm-referenced neurodevelopment assessments indicated declining standardized scores over time; however, absolute scores (i.e., age equivalent person ability scores) indicated that developmental gains were slower than average, particularly among older participants. Between-person differences in neurodevelopmental skills as a function of age did not match within-person change, suggesting a cohort effect.

conclusionsIn this cohort, CTD was associated with significant and persistent intellectual disability. The use of absolute metrics from neurodevelopmental tests (e.g., person ability scores) allowed for the quantification of slow, but present, skill development.

Indexed as

Brain Diseases, Metabolic, InbornCreatineGenetic Diseases, X-LinkedIntellectual DisabilityMovement DisordersPlasma Membrane Neurotransmitter Transport ProteinsAdolescentAdultAgedChildChild, PreschoolHumansInfantLongitudinal StudiesMaleMembrane Transport ProteinsCreatinecreatine transporterMembrane Transport ProteinsPlasma Membrane Neurotransmitter Transport ProteinsCerebral creatine deficiency syndromesCreatine transporter deficiencyIntellectual disabilitiesSLC6A8

Identifiers

PMID41260060
PMCPMC12905711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.